Ehlers-Danlos Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Ehlers-Danlos Syndrome Market Outlook

Thelansis’s “Ehlers-Danlos Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ehlers-Danlos Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Ehlers-Danlos Syndrome Overview

Ehlers-Danlos syndrome (EDS) encompasses a spectrum of connective tissue disorders distinguished by unstable, hypermobile joints, lax and resilient skin, and tissue vulnerability. Its etiology stems from a deficiency in connective tissue integrity, predominantly attributed to mutations within the collagen gene. Vascular Ehlers-Danlos syndrome (vEDS) follows an autosomal dominant inheritance pattern, with the COL3A1 gene mutation being the primary culprit. Approximately half of vEDS cases inherit the mutation from an affected parent, while the remainder arise from spontaneous mutations. Offspring of affected individuals have a 50 percent likelihood of inheriting the mutation and manifesting the disorder. The predominant subtypes of EDS include:

1. Hypermobile EDS is characterized by joint hypermobility, delicate, easily bruised skin, and persistent musculoskeletal discomfort.
2. Classical EDS: Features include stretchable skin prone to bruising, joint hypermobility, muscular weakness, and developmental delays.
3. Vascular EDS: The most severe variant, impacting cardiac function and other vital organs. Affected children may also have stature deficiencies, receding gums, and diminished subcutaneous fat.
4. Kyphoscoliosis EDS: It is typically evident at birth, with pronounced musculoskeletal fragility, delayed motor milestones, and progressive spinal curvature.
5. Arthrochalasis EDS: Manifestations include joint hypermobility, congenital hip dislocation, fragile skin prone to bruising, muscle weakness, and diminished bone density.
6. Dermatosparaxis EDS is a rare subtype characterized by extremely fragile skin prone to severe bruising, facial skin redundancy, and hernias.

The estimated prevalence of Ehlers-Danlos syndrome stands at approximately 1 in every 5,000 births.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: